Suven Pharma receives approval for Cohance Lifesciences merger

Suven Pharmaceuticals (BSE: SUVENPHAR) announced today that it has received approval from the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India, for the proposed scheme of amalgamation with Cohance Lifesciences Limited. The approval, dated April 22, 2025, satisfies requirements under the Foreign Exchange Management (Non-Debt Instruments) Rules, 2019 and relates to a potential increase in aggregate foreign investment in Suven Pharmaceuticals above 74% following the merger. The merger, under Sections 230 to 232 of the Companies Act, 2013, is planned to take effect the first day of the month after all specified conditions are met, after which it will be communicated to the stock exchanges.